Global Fungal Infections Market, By Drug Type (Echinocandins {Caspofungin, Micafungin, Anidulafungin, and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles, and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin, and Others}, Allylamines {Butenafine, Terbinafine, and Naftifine}, and Others), By Infection Type (Superficial Antifungal Infection and Systemic Antifungal Infection), By Dosage form (Drugs, Ointment, Powder, and Others), By Therapeutic Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others is known as an antifungal medicine, sometimes known as an antimycotic medication. The majority of these medications require a doctor's prescription, although a handful are available over the counter (OTC). Antifungals are divided into two categories: local and systemic. Depending on the problem being treated, local antifungals are commonly used topically or vaginally. Antifungals for the system are taken orally or intravenously. Only a few azole antifungals are utilised systemically in clinical practise. Ketoconazole, itraconazole, fluconazole, fosfluconazole, voriconazole, posaconazole, and isavuconazole are some of the drugs available. Griseofulvin and terbinafine are examples of non-azole systemic antifungals. Antifungal medications are used to detect and remove fungal diseases with minimal negative effects on the body. Unhygienic and dirty settings in which fungal agents grow promote fungal infection in the body. These agents multiply by disseminating spores, which then cause infections on the skin (superficial) or in the lungs (systemic)-fungal diseases. Candidaiasis, fungal pneumonia, mucormycosis, and other disorders are caused by a fungal infection. These infections are usually non-lethal, but in rare situations, they can be fatal. The Global Fungal Infections Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 2.52 billion by 2030 and is anticipated to register a CAGR of 3.0%.

Development of new generic and unique anti-infective pharmaceuticals

The fungal infection market is driven by key players' continued focus on the development of new generic and unique anti-infective pharmaceuticals and formulation technologies to address serious fungal infections. The different launches made by many key entities demonstrate this. Basilea Pharmaceutica Ltd., for example, launched CRESEMBA (isavuconazole) in the United Kingdom in 2016. This is a brand-new azole antifungal medication used to treat mucormycosis.

Rising occurrence of fungal diseases

The rising occurrence of fungal diseases around the world is fueling the market's expansion. Furthermore, increased use of immunosuppressive and antineoplastic drugs, prosthetic devices and grafts, and broad-spectrum antibiotics has led in an upsurge in fungal infections in recent years. According to statistics provided by the Centers for Disease Control and Prevention in 2017, over 220,000 new people are infected with cryptococcal meningitis each year, which is a brain infection that causes 181,000 deaths each year around the world. Because of the high incidence of HIV/AIDS in Sub-Saharan Africa, the majority of the deaths were reported there. Due to the significant prevalence of mycological diseases over the world, this indicates a potential market for antifungal medications. The expansion in the global geriatric population is projected to increase demand for antifungals to treat opportunistic fungal infections, as older people are more susceptible to infectious diseases and chronic disorders, such as HIV and cancer. The demand for fungistatic drugs is expected to continue robust through 2025, owing to an increase in cases of difficult-to-diagnose fungal infections that result in high mortality and morbidity rates.

                                                         Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Fungal Infections Market is segmented based on drug type, infection type, dosage form, therapeutic type and region.

On the basis of Drug Type, the Global Fungal Infections Market is segmented into Echinocandins {Caspofungin, Micafungin, Anidulafungin, and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles, and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin, and Others}, Allylamines {Butenafine, Terbinafine, and Naftifine}, and Others. Based on Infection Type, the target market is segmented into Superficial Antifungal Infection and Systemic Antifungal Infection. Based on Dosage Form, the target market is segmented into Drugs, Ointment, Powder, and Others. Based on Therapeutic Type, the target market is segmented into Aspergillosis, Dermatophytosis, Candidiasis, and Others.

Regional Insights:               

                                                                                                             Source: Prophecy Market Insights

On region the Global Fungal Infections Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America had the greatest market share. The market's expansion can be due to increased awareness of fungal infection treatment and the presence of a major target population. Due to improved healthcare facilities and increased government activities to raise public awareness of infectious diseases, Asia Pacific is expected to grow at the quickest rate throughout the projection period. The United States has one of the world's most developed economies. It currently controls a large portion of the market. Fungal illnesses in the United States have posed a challenge to the country's healthcare officials. Resistance to some strains of Candida has been discovered, according to the Centers for Disease Control and Prevention (CDC). Candida is the most common cause of healthcare-associated bloodstream infections in the United States. Fluconazole resistance is found in about 7% of all Candida bloodstream isolates examined by the CDC. Over the last two decades, this observation has remained quite consistent. Resistance to echinocandins, on the other hand, has been on the rise.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Fungal Infections Market report based on drug type, infection type, dosage form, therapeutic indication and region.

Global Fungal Infections Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

Some of the market players are Abbott Laboratories, Bayer AG, Astellas Pharma Inc., Glenmark, GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc, etc. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.

• Abbott Laboratories
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bayer AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Astellas Pharma Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Glenmark
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• GlaxoSmithKline PLC
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck & Co. Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies